SG Americas Securities LLC Grows Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

SG Americas Securities LLC lifted its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 11.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,944 shares of the company’s stock after purchasing an additional 4,799 shares during the quarter. SG Americas Securities LLC’s holdings in Adaptive Biotechnologies were worth $275,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. JTC Employer Solutions Trustee Ltd acquired a new stake in Adaptive Biotechnologies during the third quarter valued at $26,000. Ashton Thomas Securities LLC purchased a new stake in shares of Adaptive Biotechnologies during the 3rd quarter worth about $34,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Adaptive Biotechnologies during the 2nd quarter valued at about $49,000. Townsquare Capital LLC purchased a new position in shares of Adaptive Biotechnologies in the 3rd quarter valued at about $56,000. Finally, GAMMA Investing LLC acquired a new position in Adaptive Biotechnologies in the 4th quarter worth about $59,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Trading Up 9.2 %

NASDAQ:ADPT opened at $8.05 on Thursday. The firm has a market cap of $1.19 billion, a P/E ratio of -6.01 and a beta of 1.49. The stock has a 50 day moving average of $6.76 and a two-hundred day moving average of $5.47. Adaptive Biotechnologies Co. has a 12 month low of $2.28 and a 12 month high of $8.33.

Wall Street Analyst Weigh In

ADPT has been the topic of several research analyst reports. The Goldman Sachs Group raised their price objective on Adaptive Biotechnologies from $5.50 to $7.50 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Piper Sandler lifted their price target on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Finally, BTIG Research upped their price objective on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.